EXPERIENCE THE ART OF SCIENCE
Pfizer CentreOne Development Services
We conquer complexity with imagination and intelligence. Our years of experience mean there are few challenges we haven’t faced. We have problem-solving down to a fine art.
Collaborative. Creative. Considered.
We are backed by the scientific power and regulatory expertise of Pfizer:
• Over 90 new products in Pfizer’s drug development pipeline
• More than 400 tech transfers in various stages a year
• Regulatory experience supporting 60+ countries
Draw upon the scientific power of Pfizer to shape your development masterpiece
|
|
BioPharmGuy
We are beginning to split out the service providers in our directory into more specific categories. We currently have headings like Contract Research and Scientific Services which are a little too broad. If you have suggestions for how we can best segment specific types of companies by capability, we would love your input, so please send us an email.
Speaking of sending us email - we don’t get weird emails as often as we used to, but animal-related requests have always been our favorites. Got this one last week:
“I was wondering who I could get ahold of for obtaining information about any companies that deal with bee venom? I'm from New Zealand so the email above is the best way to get ahold of me, cheers.”
Could this ‘bee’ the latest quack Covid cure?
Monthly Funding Summary
Things are definitely silent on the public markets – a measly three IPOs in February, one of which was in France. Total IPO take was $170M. Worst month in forever.
As for private companies, their funding continued at a relatively strong pace with 50 companies bringing in $2.6B. Eight of these rounds were $100M+. Rich people still got a lot of money they have to put somewhere and the stock market looks like a dog with interest rates rising.
Excel version of our monthly funding rundown is available on the downloads page.
Companies Added & Removed
Our monthly link check led to 28 companies being extirpated. We added 11 new ones.
Best New Name:
You Will Be Missed:
Cobra Biologics
You Won't be Missed:
Thrive Earlier Detection
|
|
J&J/Legend Biotech
FDA approved their product, Carvykti, for relapsed or refractory multiple myeloma. In the clinical trial 98% of patients responded, which is basically unheard of in a cancer trial. Maybe there’s something to this whole biotechnology thing? Great news for MM patients and their loved ones.
ZimVie
If this whole story is imbuing you with a sense of déjà vu, that's likely because back in 2013 Abbott Labs decided to spin out their therapeutics business into a new publicly traded company, which they named AbbVie.
History may not repeat, but at least in this case, it definitely rhymes.
Secret Pipeline
Some companies don’t want to share the specifics of the drugs they're currently working on, which is fine. In those cases, they generally just don’t say what they they’re working on. Occasionally they state that they are in stealth or the products are undisclosed.
But here we have another tactic. This company decided to publish a blurred-out image of a drug pipeline after having already let the visitor know the info is “currently undisclosed”. Come on man, downloading those unnecessary images is wasting precious Internet minutes for those 112 AOL subscribers out there.
Here Come the Smart People
Company out of Northern CA is genetically modifying trees to grow faster and also absorb metals from the soil. This would be a good idea if the goal is a more efficiently-grown and cost-effective commercial crop. Alas, their stated goal is to sequester more carbon.
Uhhh, sure, or you could just plant twice as many trees and skip all this. Any lack of trees, at least in America, is really a manpower problem, not a tree growth problem. Most landowners would say “sure” if you asked if you could plant trees for free on their vacant property. Not sure any landowner is going to pay quadruple or more for a genetically modified tree when they could more cheaply plant two regular ones.
Silicon Valley: Adding unnecessary complexity since 1971.
VuEssence
If you were hoping to get a job at this company down in Odessa, FL you're probably out of luck. We say probably because as they say:
We are currently “not accepting” applications as we have staffed our laboratory.
So they're "not accepting" applications, eh? Sounds like the beginnings of a negotiation...
The Dropout
The latest media attempt at profiting off Elizabeth Holmes' misdeeds at Theranos is a Hulu miniseries called The Dropout. Three episodes were released today, with an additional episode to be available each week until April 7. (We were not able to screen any episodes this morning, but you may get our unbiased review in the near future.)
The IMDB episode guide leads us to believe this will last several seasons as the 8th episode only gets to the earth-shattering WSJ article, whereas the best parts of the saga come after that.
|
|
How to Reduce the Complexity of Single-Use Systems
Genderless connectors are commonly used in single-use systems. Learn five key benefits of genderless aseptic connectors and how they can lead to more flexibility, reduced risk and lower costs for your company. Learn More
Qosina is pleased to offer the full line of AseptiQuik® and MicroCNX™ genderless connectors.
We are a global supplier of single-use components and offer a comprehensive selection of parts for the design, development and manufacture of single-use systems for bioprocessing.
|
|
All Work and Nobel
The Broad Institute, which has been fighting a patent battle over CRISPR with the University of California, won yet another round relating to CRISPR use in eukaryotes. UC’s Jennifer Doudna (along with Emmanuelle Charpentier) is pretty much universally recognized as having figured things out first, but in prokaryotes (bacteria/archaea). Feng Zheng at MIT/Broad then successfully did so in eukaryotic cells (which is the branch of life that includes animals), and duly slapped a patent on that.
Doudna received a Nobel prize, but Zheng was awarded the much bigger financial prize: the US patents for CRISPR in animal cells. This latest victory reaffirms that any human therapies based on CRISPR will require a license from Broad, and while it's not a kitten mitten-caliber patent, it's going to be a cash cow for years to come.
FTC Has Questions
The middlemen in the pharmaceutical industry who are partially, if not wholly, responsible for the opacity of drug pricing in America are about to be put to the test by the Federal Trade Commission. The FTC put out a call for public input into how these Pharmacy Benefit Managers are affecting drug affordability.
If you would like to understand how PBMs affect drug pricing, it’s not for the faint of heart, but here’s a start.
Alcohol Enables Drinking
Ohio State researchers conducted a study and tracked alcohol consumption amongst parents of young children. They were able to conclude that parents who lived/worked/shopped near more bars and restaurants drank more alcohol.
Amazing! Who knew that the availability of a product could be linked to its rate of consumption? Maybe their next study will analyze whether people who live next to Taco Bell eat more Crunchwraps than people who live 10 miles away.
Africa CDC: Slow Your Rollout
|
|
ETC.
It’s Britney, Nerd
You may have thought Britney Spears spent her whole life dancing, singing and suing her father for access to her own money. But did you know she also had time to create some useful semiconductor physics lessons back in the early 2000s? Study up!
|
|
BioPharmGuy is a registered trademark of Wilsonian LLC, Content © 2022 Wilsonian LLC |
|
Check your website's analytics - we are likely one of your top referrers. You may be able to boost those referrals with a Premium Listing. Read more here: Promoted Listings.
Send us a message if you have questions or are interested.
|
|
|
|
|
|
|
|
